Cleveland BioLabs - 48 Year Dividend History | CBLI

Historical dividend payout and yield for Cleveland BioLabs (CBLI) since 1971. The current TTM dividend payout for Cleveland BioLabs (CBLI) as of April 18, 2019 is $0.00. The current dividend yield for Cleveland BioLabs as of April 18, 2019 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.017B $0.001B
CLEVELAND BIOLABS, INC. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. The Company's proprietary technology platform is based on the ability to suppress or stimulate programmed cell death (apoptosis). CBLI's drugs can switch apoptosis on and off by affecting key regulators of cell response to stresses, such as radiation or ischemia. CBLI is pursuing three key areas of research: Biodefense for Acute Radiation Syndrome, Cancer Treatment, and Tissue Protection.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $109.313B 12.32
Gilead Sciences (GILD) United States $80.293B 10.22
Bio-Techne Corp (TECH) United States $7.144B 48.13